Eastgate Biotech Engages Agent to Identify Suitable Joint Venture Partners and Suppliers in the Philippines
Mandate also includes collaboration with local hospital for innovative Surgical and Anti-Aging procedures
(Newswire.com) - EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company that develops innovative pharmaceutical products and produces and distributes innovative and healthy nutraceuticals based on natural therapies has announced that it has engaged the services of an agent affiliated with the Philippines pharmaceutical industry to seek out suitable joint venture partners and suppliers in the Philippines.
The agent, Roger Munoz, a principal of i-Power Philippines, a subsidiary of the ICube Group (www.icube.ph) a large holding group mostly for Nippon SME business in the Philippines, will work together with the company’s own Global Business Development team to act in EastGate’s interests in identifying local partners for the purposes of clinical testing, registration and marketing of the company’s diabetes-cardiovascular related products including its OTC products and the pharmaceutical product pipeline being developed by EastGate (www.EastGateBiotech.com).
According to the World Health Organization, the Philippines is considered a diabetes hotspot. Presently, 1 out of every 5 Filipinos has diabetes representing 20% of the population. It is predicted that the Philippines will be part of the top 10 countries affected by diabetes due to the accelerated rate of its citizens developing the disease.
The agent, also has a mandate within his own personal capacity to establish collaborations with local hospitals looking to introduce innovative anti-aging treatments and surgical procedures to be provided by EastGate’s wholly-owned subsidiary, OMNI Surgery + Anti-Aging Center (www.OmniSurgery.ca). The agent is already collaborating with a local Neurologist specialist for the purpose of attracting innovation to the Philippines.
“We are excited about establishing Joint Venture partnerships in this emerging and growing Philippines market,” states Anna Gluskin, EastGate’s CEO. “This effort will complement our ongoing business development activities and inroads in other densely-populated diabetes countries in the SEA region. From our early discussions that have been initiated in the Philippines and due to the growing concern for disease management we anticipate that we will be able to enter into productive and viable partnerships in the Philippines soon,” concluded Gluski
